Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial - PubMed (original) (raw)
Clinical Trial
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
Steven R Smith et al. Metabolism. 2005 Jan.
Abstract
Background: Several clinical studies have demonstrated that body weight increases after treatment with thiazolidinediones (TZDs). Prior studies have demonstrated an increase in insulin-stimulated lipid storage in adipose tissue. Some, but not all, studies demonstrate reductions in visceral adipose tissue. Changes in body weight are the result of changes in energy intake, energy expenditure, or both.
Objectives: Based on these findings, the primary aim of this study was to evaluate the effect of TZDs on visceral, subcutaneous, and total body fat. Secondary aims were to determine the effects of pioglitazone on (a) energy expenditure, (b) hunger and satiety, (c) blood lipids, and (d) the role of insulinemia/sulfonylurea usage on weight gain in patients with type 2 diabetes.
Subjects and methods: We performed a randomized, double-blind, placebo-controlled trial in 48 men and women with type 2 diabetes who had not previously received treatment with TZDs. Patients were treated for 24 weeks with 45 mg/d of pioglitazone or a matching placebo. Body composition was measured by dual-energy x-ray absorptiometry. Visceral and subcutaneous fat were measured by computed tomography. Resting metabolic rate and thermogenic response to a test meal were measured by indirect calorimetry before and after a standardized meal. Hunger and satiety were measured with visual analog scales before and after the same test meal. Blood was collected for the measurement of fasting glucose and insulin levels, hemoglobin A 1c levels, and lipid content.
Results: Pioglitazone treatment resulted in a decrease in hemoglobin A(1c) level by 0.96 +/- 1.1% vs 0.11 +/- 0.8% in the placebo group (P < .005). Body weight and fat increased steadily in the patients treated with pioglitazone during the 6 months of the study (+3.9 +/- 3.1 kg at 6 months in pioglitazone-treated patients vs -0.8 +/- 3.4 kg in the placebo-treated patients). Subcutaneous fat in the trunk, arms, and legs were all increased in the pioglitazone-treated group. Visceral fat did not change significantly in either group. Neither resting metabolic rate nor the thermogenic responses to a meal were altered by pioglitazone. Subjective measures of hunger (visual analog scale) did not change with pioglitazone treatment. Triglycerides fell in the pioglitazone-treated group (-58.5 +/- 124 mg/dL, P < .003). Neither the prior use of sulfonylureas nor the level of insulinemia before treatment was a predictor of weight or fat change.
Conclusion: Pioglitazone increased subcutaneous body fat, but not visceral fat. There was no measurable effect on energy expenditure or hunger/satiety. In contrast to the placebo-treated patient with diabetes, weight gain occurs in the face of falling hemoglobin A(1c) and triglyceride levels.
Similar articles
- Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P, Henry RR. Shah PK, et al. Diabetes Obes Metab. 2011 Jun;13(6):505-10. doi: 10.1111/j.1463-1326.2011.01370.x. Diabetes Obes Metab. 2011. PMID: 21272186 Free PMC article. Clinical Trial. - Efficacy and safety of the PPARĪ³ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C; BALLET Trial Investigators. Henriksen K, et al. Diabetes Metab Res Rev. 2011 May;27(4):392-401. doi: 10.1002/dmrr.1187. Diabetes Metab Res Rev. 2011. PMID: 21328517 Clinical Trial. - Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, Boyland EJ, Kemp GJ, Cuthbertson DJ, Wilding JP. Rajeev SP, et al. BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539. BMJ Open. 2017. PMID: 28132008 Free PMC article. Clinical Trial. - Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Dormandy J, et al. Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002. Drug Saf. 2009. PMID: 19338377 Review. - Recent findings concerning thiazolidinediones in the treatment of diabetes.
Boden G, Zhang M. Boden G, et al. Expert Opin Investig Drugs. 2006 Mar;15(3):243-50. doi: 10.1517/13543784.15.3.243. Expert Opin Investig Drugs. 2006. PMID: 16503761 Review.
Cited by
- Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, Zhang Y, Shen S, Tong N. Lu X, et al. Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi: 10.1038/s41392-024-01951-9. Signal Transduct Target Ther. 2024. PMID: 39353925 Free PMC article. Review. - Adipose Tissue Dysfunction Determines Lipotoxicity and Triggers the Metabolic Syndrome: Current Challenges and Clinical Perspectives.
Carobbio S, Pellegrinelli V, Vidal-Puig A. Carobbio S, et al. Adv Exp Med Biol. 2024;1460:231-272. doi: 10.1007/978-3-031-63657-8_8. Adv Exp Med Biol. 2024. PMID: 39287854 Review. - Preclinical Multi-Omic Assessment of Pioglitazone in Skeletal Muscles of Mice Implanted with Human HER2/neu Overexpressing Breast Cancer Xenografts.
Clayton SA, Mizener AD, Whetsell M, Rentz LE, Meadows E, Geldenhuys W, Pistilli EE. Clayton SA, et al. bioRxiv [Preprint]. 2024 Apr 20:2024.04.15.589557. doi: 10.1101/2024.04.15.589557. bioRxiv. 2024. PMID: 38659807 Free PMC article. Preprint. - Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age.
Lisco G, Disoteo OE, De Tullio A, De Geronimo V, Giagulli VA, Monzani F, Jirillo E, Cozzi R, Guastamacchia E, De Pergola G, Triggiani V. Lisco G, et al. Nutrients. 2023 Dec 25;16(1):63. doi: 10.3390/nu16010063. Nutrients. 2023. PMID: 38201893 Free PMC article. Review. - DNA Methylation at ABCG1 and Long-term Changes in Adiposity and Fat Distribution in Response to Dietary Interventions: The POUNDS Lost Trial.
Li X, Shao X, Kou M, Wang X, Ma H, Grundberg E, Bazzano LA, Smith SR, Bray GA, Sacks FM, Qi L. Li X, et al. Diabetes Care. 2023 Dec 1;46(12):2201-2207. doi: 10.2337/dc23-0748. Diabetes Care. 2023. PMID: 37770056
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical